saniva diagnostics GmbH

About Xlife Sciences

Xlife Sciences AG operates a unique value-creation platform model, identifying and de-risking early-stage life science innovations from academic origins. Its strategy involves forming dedicated project companies, providing capital and operational support to achieve pre-clinical proof-of-concept, and targeting exits within 2-3 years via trade sales or licensing. Recent achievements include the announced exit of 12 project companies to Grupo Landsteiner and progress toward a NASDAQ listing for its portfolio company VERAXA Biotech, highlighting its execution on the value inflection strategy.

Therapeutic Areas